Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI)
J-ADNI was launched in 2008, aiming at conducting a longitudinal workup of a standardized neuroimaging, biomarker, and clinico-psychological surveys. At baseline, the project included over 530 participants who had either normal cognition (CN), late amnestic mild cognitive impairment (LMCI), or mild Alzheimer's disease (AD). Participants were volunteers between the ages of 60 and 84 years, and were enrolled across 38 participating clinical sites throughout Japan. from August 2008 to April 2012. The research protocol was designed to maximise compatibility with US-ADNI, the United States branch of the initiative.
Study design
Cohort
Number of participants at first data collection
154 (CN participants)
234 (LMCI participants)
149 (AD participants)
Recruitment is ongoing
Age at first data collection
60 - 84 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Country
Year of first data collection
2008
Primary Institutions
University of Tokyo (東京大学, UTokyo)
Profile paper DOI
Funders
Astellas Pharma Inc. (アステラス製薬株式会社)
Bristol-Myers Squibb (BMS)
Daiichi Sankyo Co., Ltd. (第一三共株式会社)
Dainippon Sumitomo Pharma (now known as Sumitomo Pharma Co., Ltd., 住友ファーマ株式会社)
Eisai Co., Ltd. (エーザイ株式会社)
Ongoing?
Yes
Data types collected
- Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
- Interview – unspecified
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- None
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- None
Engagement
Keywords
Consortia and dataset groups
